Tg Therapeutics (TGTX) Current Deferred Revenue (2012 - 2026)
Tg Therapeutics (TGTX) posted quarterly Current Deferred Revenue of $17.2 million for Q1 2026, up 0.65% year-over-year from $17.1 million in Q1 2025, and down 19.04% quarter-over-quarter from $21.2 million in Q4 2025.
Tg Therapeutics (TGTX) Current Deferred Revenue (2012 - 2026) Analysis & Trends
Tg Therapeutics' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $17.2 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 0.65% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $17.2 million (up 0.65% YoY), while the FY2025 annual figure was $21.2 million, up 86.03% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $17.2 million, down from $21.2 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $26.4 million in Q3 2025, with the low at $152000.0 in Q4 2023.
- The 5-year median for Current Deferred Revenue is $3.4 million (2024), against an average of $8.4 million.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue sank 69.6% in 2023, then surged 7409.21% in 2024.
- Tg Therapeutics' Current Deferred Revenue stood at $500000.0 in 2022, then tumbled by 69.6% to $152000.0 in 2023, then soared by 7409.21% to $11.4 million in 2024, then jumped by 86.03% to $21.2 million in 2025, then fell by 19.04% to $17.2 million in 2026.
- Business Quant data shows TGTX's Current Deferred Revenue at $17.2 million in Q1 2026, $21.2 million in Q4 2025, and $26.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.83 Mn |
| Mar 31, 2026 | 17.19 Mn |
| Dec 31, 2025 | 21.23 Mn |
| Sep 30, 2025 | 26.40 Mn |
| Jun 30, 2025 | 23.91 Mn |
| Mar 31, 2025 | 17.08 Mn |
| Dec 31, 2024 | 11.41 Mn |
| Sep 30, 2024 | 9.09 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 3.37 Mn |
| Dec 31, 2023 | 152,000.00 |
| Sep 30, 2023 | 6.90 Mn |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 400,000.00 |
| Dec 31, 2022 | 500,000.00 |
| Sep 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 600,000.00 |
| Dec 31, 2021 | 600,000.00 |
| Sep 30, 2021 | 600,000.00 |